{"id":2063,"date":"2025-02-17T09:00:16","date_gmt":"2025-02-17T08:00:16","guid":{"rendered":"https:\/\/www.access2meds.eu\/?p=2063"},"modified":"2025-02-17T09:00:19","modified_gmt":"2025-02-17T08:00:19","slug":"3-things-about-reimbursement-the-fourth-video-in-our-series","status":"publish","type":"post","link":"https:\/\/www.access2meds.eu\/hr\/3-things-about-reimbursement-the-fourth-video-in-our-series\/","title":{"rendered":"&#8220;3 Things About Reimbursement&#8221; \u2013 The fourth Video in Our Series!"},"content":{"rendered":"\n<p>We\u2019re excited to launch &#8220;3 Things About Reimbursement&#8221;, the fourth video in our &#8216;3 Things About&#8217; series designed to simplify complex healthcare topics. In this video, <a href=\"https:\/\/www.linkedin.com\/in\/fthielen\/\">Frederick Thielen<\/a> explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"558\" src=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/01\/reimbursement-1024x558.png\" alt=\"\" class=\"wp-image-1983\" srcset=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/01\/reimbursement-980x534.png 980w, https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/01\/reimbursement-480x262.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<h5 class=\"wp-block-heading\" id=\"h-click-here-to-watch\"><a href=\"https:\/\/youtu.be\/e36OtJA90Qg\">Click here to watch.<\/a><\/h5>\n<\/div>\n<\/div>\n\n\n\n<p><\/p>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-transcript-of-the-video\">Transcript of the video<\/h5>\n\n\n\n<p>3 THINGS ABOUT REIMBURSEMENT<\/p>\n\n\n\n<p>Looking at the European Union, you may notice that some medicines are available in one Member State but not in another. This happens even though the European Medicines Agency decides if a drug is effective and&nbsp; safe and can be sold in all EU countries. So, how is it possible that a medicine is legal to sell across the EU but is not available in every Member State?<\/p>\n\n\n\n<p>The reason for this lies in the complex process of drug reimbursement. Just because a drug is legal to sell does not mean that every Member State is willing or able to pay for it. Drug reimbursement plays a crucial role in ensuring that patients have access to necessary medications without bearing the full financial burden. Yet, many aspects of this process remain unseen by the public. Here are three things you might not know about drug reimbursement:<\/p>\n\n\n\n<p><strong>Different evaluation processes<\/strong><\/p>\n\n\n\n<p>Each EU Member State has its own process for deciding which drugs will be reimbursed and at what price. The EU Treaty of Maastricht, signed in 1992, gave the EU the authority to make central decisions on certain health policies, such as the safety and approval of medicines through the EMA. However, the financing of healthcare systems\u2014including how drugs are reimbursed\u2014was and still is deliberately left to each individual Member State.<\/p>\n\n\n\n<p>This means that while the EMA ensures a drug is safe, effective and can be marketed across the EU, each country then decides if its healthcare system will cover the cost of that drug for patients. Some countries have specialised bodies, called Health Technology Assessment agencies, that evaluate how well a drug works and whether its price is justified based on the promised health benefits. The goal of this process is not just to cut costs or find reasons to say no, as some might believe, but to ensure that patients have access to drugs that provide meaningful health benefits relative to their costs.<\/p>\n\n\n\n<p><strong>Impact of negotiations and pricing agreements<\/strong><\/p>\n\n\n\n<p>The final price of a drug is often settled after lengthy negotiations between pharmaceutical companies and the bodies who are responsible for the expenditures on drugs, like ministries of Health, national health services or insurance companies. These negotiations can lead to confidential discounts, rebates which are certain types of discounts or refunds, and even value-based agreements where payment is tied to how well the drug performs in the real world.<\/p>\n\n\n\n<p>These pricing agreements aim to align everyone&#8217;s interests: ensuring that patients get effective treatments while helping healthcare systems manage their budgets. It is a balancing act between making sure innovative drugs are accessible and healthcare costs are sustainable.<\/p>\n\n\n\n<p><strong>Differences in Patient Access<\/strong><\/p>\n\n\n\n<p>Drug reimbursement policies vary significantly across different countries and even within regions of the same country. Factors such as local healthcare priorities, economic conditions, and regulatory frameworks influence these policies. This variability means that a drug available through reimbursement in one country or region might not be reimbursed in another. This affects its accessibility and affordability for patients depending on their geographic location.<\/p>\n\n\n\n<p>And even when a drug is reimbursed, patient access can still vary. Some countries may choose to cover a drug for all eligible patients, while others might impose certain restrictions\u2014for example, only reimbursing it for specific conditions or for patients who have already tried other treatments.&nbsp;<\/p>\n\n\n\n<p>There is a lot of nuance behind these decisions and each country is trying to make the best choice for its population, given the available budget and political context. By continuing to innovate, collaborate, and adapt, we can move closer to a future where equitable access to effective treatments is a reality for all.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-and-don-t-miss-the-making-of-video\">And don&#8217;t miss the making-of video<\/h5>\n\n\n\n<p>The videos were filmed on November 28, 2024, at the Gegevens Erasmus Studio of Erasmus University Rotterdam. <\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"540\" src=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/12\/making-of-2-1024x540.png\" alt=\"\" class=\"wp-image-1970\" srcset=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/12\/making-of-2-980x517.png 980w, https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/12\/making-of-2-480x253.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/12\/making-of-1024x536.png\" alt=\"\" class=\"wp-image-1971\" srcset=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/12\/making-of-980x513.png 980w, https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/12\/making-of-480x251.png 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n<\/div>\n<\/div>\n\n\n\n<p><a href=\"https:\/\/www.youtube.com\/watch?v=JjYDG7BDNDE\">Watch here.<\/a><\/p>\n\n\n\n<p>We invite you to watch, share, and join the conversation about how we can work together to make healthcare more equitable and effective.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>We\u2019re excited to launch &#8220;3 Things About Reimbursement&#8221;, the fourth video in our &#8216;3 Things About&#8217; series designed to simplify complex healthcare topics. In this video, Frederick Thielen explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.<\/p>\n","protected":false},"author":5,"featured_media":1450,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[14],"class_list":["post-2063","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-allgemein","tag-healthcare"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.8 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>&quot;3 Things About Reimbursement&quot; \u2013 The fourth Video in Our Series! - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"We\u2019re excited to launch &quot;3 Things About Reimbursement&quot;, the fourth video in our &#039;3 Things About&#039; series designed to simplify complex healthcare topics. In this video, Frederick Thielen explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/\" \/>\n<meta property=\"og:locale\" content=\"hr_HR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"&quot;3 Things About Reimbursement&quot; \u2013 The fourth Video in Our Series!\" \/>\n<meta property=\"og:description\" content=\"We\u2019re excited to launch &quot;3 Things About Reimbursement&quot;, the fourth video in our &#039;3 Things About&#039; series designed to simplify complex healthcare topics. In this video, Frederick Thielen explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-17T08:00:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-17T08:00:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2005\" \/>\n\t<meta property=\"og:image:height\" content=\"1254\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lena Jessen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Napisao\/la\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lena Jessen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Procijenjeno vrijeme \u010ditanja\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuta\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/\"},\"author\":{\"name\":\"Lena Jessen\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/person\\\/84cb4791d2eba62e68ecb7f29dba9391\"},\"headline\":\"&#8220;3 Things About Reimbursement&#8221; \u2013 The fourth Video in Our Series!\",\"datePublished\":\"2025-02-17T08:00:16+00:00\",\"dateModified\":\"2025-02-17T08:00:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/\"},\"wordCount\":739,\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"keywords\":[\"healthcare\"],\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"hr\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/\",\"name\":\"\\\"3 Things About Reimbursement\\\" \u2013 The fourth Video in Our Series! - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"datePublished\":\"2025-02-17T08:00:16+00:00\",\"dateModified\":\"2025-02-17T08:00:19+00:00\",\"description\":\"We\u2019re excited to launch \\\"3 Things About Reimbursement\\\", the fourth video in our '3 Things About' series designed to simplify complex healthcare topics. In this video, Frederick Thielen explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/#breadcrumb\"},\"inLanguage\":\"hr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"width\":2005,\"height\":1254},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/3-things-about-reimbursement-the-fourth-video-in-our-series\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/hr\\\/pocetna-stranica\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"&#8220;3 Things About Reimbursement&#8221; \u2013 The fourth Video in Our Series!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"hr\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/person\\\/84cb4791d2eba62e68ecb7f29dba9391\",\"name\":\"Lena Jessen\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\"3 Things About Reimbursement\" \u2013 The fourth Video in Our Series! - ASCERTAIN","description":"We\u2019re excited to launch \"3 Things About Reimbursement\", the fourth video in our '3 Things About' series designed to simplify complex healthcare topics. In this video, Frederick Thielen explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/","og_locale":"hr_HR","og_type":"article","og_title":"\"3 Things About Reimbursement\" \u2013 The fourth Video in Our Series!","og_description":"We\u2019re excited to launch \"3 Things About Reimbursement\", the fourth video in our '3 Things About' series designed to simplify complex healthcare topics. In this video, Frederick Thielen explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.","og_url":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/","og_site_name":"ASCERTAIN","article_published_time":"2025-02-17T08:00:16+00:00","article_modified_time":"2025-02-17T08:00:19+00:00","og_image":[{"width":2005,"height":1254,"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","type":"image\/jpeg"}],"author":"Lena Jessen","twitter_card":"summary_large_image","twitter_creator":"@ASCERTAIN_EU","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Napisao\/la":"Lena Jessen","Procijenjeno vrijeme \u010ditanja":"5 minuta"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/#article","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/"},"author":{"name":"Lena Jessen","@id":"https:\/\/www.access2meds.eu\/#\/schema\/person\/84cb4791d2eba62e68ecb7f29dba9391"},"headline":"&#8220;3 Things About Reimbursement&#8221; \u2013 The fourth Video in Our Series!","datePublished":"2025-02-17T08:00:16+00:00","dateModified":"2025-02-17T08:00:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/"},"wordCount":739,"publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"image":{"@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","keywords":["healthcare"],"articleSection":["Allgemein"],"inLanguage":"hr"},{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/","url":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/","name":"\"3 Things About Reimbursement\" \u2013 The fourth Video in Our Series! - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","datePublished":"2025-02-17T08:00:16+00:00","dateModified":"2025-02-17T08:00:19+00:00","description":"We\u2019re excited to launch \"3 Things About Reimbursement\", the fourth video in our '3 Things About' series designed to simplify complex healthcare topics. In this video, Frederick Thielen explores the complexities of drug reimbursement\u2014a key factor in ensuring patient access to new medicines. While a drug may be approved for use across the EU, reimbursement decisions vary by country, affecting its availability.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/#breadcrumb"},"inLanguage":"hr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/"]}]},{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","width":2005,"height":1254},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/3-things-about-reimbursement-the-fourth-video-in-our-series\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/hr\/pocetna-stranica\/"},{"@type":"ListItem","position":2,"name":"&#8220;3 Things About Reimbursement&#8221; \u2013 The fourth Video in Our Series!"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"hr"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]},{"@type":"Person","@id":"https:\/\/www.access2meds.eu\/#\/schema\/person\/84cb4791d2eba62e68ecb7f29dba9391","name":"Lena Jessen"}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/posts\/2063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/comments?post=2063"}],"version-history":[{"count":3,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/posts\/2063\/revisions"}],"predecessor-version":[{"id":2066,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/posts\/2063\/revisions\/2066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/media\/1450"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/media?parent=2063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/categories?post=2063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.access2meds.eu\/hr\/wp-json\/wp\/v2\/tags?post=2063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}